{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Veltri G"],"funding":["Associazione Italiana per la Ricerca sul Cancro","Fondazione Cassa di Risparmio di Padova e Rovigo","Fondazione Umberto Veronesi","Associazione Italiana Contro le Leucemie-Linfomi e Mieloma","Associazione Italiana per la ricerca sul cancro","Fondazione Città della Speranza Istituto di Ricerca Pediatrica","progetti di rilevante interesse nazionale"],"pagination":["3724"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8345121"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(15)"],"pubmed_abstract":["Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma in childhood, mainly of T cell origin (T-LBL). Although current treatment protocols allow a complete remission in 85% of cases, the second-line treatment overall survival for patients with progressive or relapsed disease is around 14%, making this the major issue to be confronted. Thus, we performed a Reverse Phase Protein Array study in a cohort of 22 T-LBL patients to find reliable disease risk marker(s) and new therapeutic targets to improve pediatric T-LBL patients' outcome. Interestingly, we pinpointed JAK2 Y1007-1008 as a potential prognosis marker as well as a therapeutic target in poor prognosis patients. Hence, the hyperactivation of the JAK1/2-STAT6 pathway characterizes these latter patients. Mor"],"journal":["Cancers"],"pubmed_title":["Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients."],"pmcid":["PMC8345121"],"funding_grant_id":["19/08","17/07_1FCR","21771","20178S4EK9","AIL-TV","19186","2064"],"pubmed_authors":["Gallingani I","Serafin V","Veltri G","Mussolin L","Bresolin S","Lovisa F","Carraro E","Vencato S","Sandei M","Biffi A","Accordi B","Pillon M","Silvestri C","Cortese G","Basso G"],"additional_accession":[]},"is_claimable":false,"name":"Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients.","description":"Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma in childhood, mainly of T cell origin (T-LBL). Although current treatment protocols allow a complete remission in 85% of cases, the second-line treatment overall survival for patients with progressive or relapsed disease is around 14%, making this the major issue to be confronted. Thus, we performed a Reverse Phase Protein Array study in a cohort of 22 T-LBL patients to find reliable disease risk marker(s) and new therapeutic targets to improve pediatric T-LBL patients' outcome. Interestingly, we pinpointed JAK2 Y1007-1008 as a potential prognosis marker as well as a therapeutic target in poor prognosis patients. Hence, the hyperactivation of the JAK1/2-STAT6 pathway characterizes these latter patients. Mor","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-04-08T07:48:02.646Z","creation":"2022-02-11T05:45:52.51Z"},"accession":"S-EPMC8345121","cross_references":{"pubmed":["34359628"],"doi":["10.3390/cancers13153724"]}}